Market Overview

UPDATE: Bank of America Raises PO to $7 on Arena Pharmaceuticals on Lorcaserin Aproval

Share:
Related ARNA
Mid-Afternoon Market Update: Portola Climbs On FDA Approval For Bevyxxa; American Software Shares Plunge
Mid-Day Market Update: Bed Bath & Beyond Drops Following Disappointing Earnings; Synchronoss Technologies Shares Surge

Bank of America reiterates its Underperform rating on Arena Pharmaceuticals (NASDAQ: ARNA) but raises its price target from $5 to $7.

Bank of America comments, "Following FDA approval of ARNA's obesity drug lorcaserin (trade name Belviq), we raised our NPV to $7/sh (from $5). Our caution on the stock has been due to a combination of delay expectations and a modest market opportunity. This latter concern is unchanged based on the drug's marginal efficacy (3-4% PBO-adjusted weight loss) and various safety concerns. With an EV of $2.3bn versus $2.5bn for VVUS, we view ARNA's current valuation as rich and remain Underperform."

ARNA closed at $11.39 on Wednesday.

Latest Ratings for ARNA

DateFirmActionFromTo
Jun 2017Cantor FitzgeraldInitiates Coverage OnOverweight
May 2017Leerink SwannInitiates Coverage OnOutperform
Sep 2016FBR CapitalInitiates Coverage onOutperform

View More Analyst Ratings for ARNA
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Reiteration Intraday Update Analyst Ratings

 

Related Articles (ARNA)

View Comments and Join the Discussion!